Publications

  1. Haddad AQ, Wood CG, Abel EJ, Krabbe LM, Darwish OM, Thompson RH, Heckman JE, Merril MM, Gayed BA, Sagalowsky AI, Boorjian SA, Margulis V, Leibovich BC. Oncologic outcomes following surgical resection of renal cell carcinoma with inferior vena caval thrombus extending above the hepatic veins: a contemporary multicenter cohort. J Urol. 2014 Oct; 192(4):1050-6. Epub 2014 Apr 02.
    View PubMed
  2. Psutka SP, Carrasco A, Schmit GD, Moynagh MR, Boorjian SA, Frank I, Stewart SB, Thapa P, Tarrell RF, Cheville JC, Tollefson MK. Sarcopenia in patients with bladder cancer undergoing radical cystectomy: Impact on cancer-specific and all-cause mortality. Cancer. 2014 Sep 15; 120(18):2910-8. Epub 2014 May 19.
    View PubMed
  3. Abel EJ, Linder BJ, Bauman TM, Bauer RM, Thompson RH, Thapa P, Devon ON, Tarrell RF, Frank I, Jarrard DF, Downs TM, Boorjian SA. Perioperative Blood Transfusion and Radical Cystectomy: Does Timing of Transfusion Affect Bladder Cancer Mortality? Eur Urol. 2014 Sep 03.
    View PubMed
  4. Linder BJ, Thompson RH, Leibovich BC, Cheville JC, Lohse CM, Gastineau DA, Boorjian SA. The impact of perioperative blood transfusion on survival after nephrectomy for non-metastatic renal cell carcinoma (RCC). BJU Int. 2014 Sep; 114(3):368-74. Epub 2014 Jan 29.
    View PubMed
  5. Briganti A, Karnes RJ, Joniau S, Boorjian SA, Cozzarini C, Gandaglia G, Hinkelbein W, Haustermans K, Tombal B, Shariat S, Sun M, Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T. Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy. Eur Urol. 2014 Sep; 66(3):479-86. Epub 2013 Dec 12
    View PubMed
  6. Schmit GD, Schenck LA, Thompson RH, Boorjian SA, Kurup AN, Weisbrod AJ, Kor DJ, Callstrom MR, Atwell TD, Carter RE. Predicting renal cryoablation complications: new risk score based on tumor size and location and patient history. Radiology. 2014 Sep; 272(3):903-10. Epub 2014 May 7
    View PubMed
  7. Abel EJ, Thompson RH, Margulis V, Heckman JE, Merril MM, Darwish OM, Krabbe LM, Boorjian SA, Leibovich BC, Wood CG. Perioperative outcomes following surgical resection of renal cell carcinoma with inferior vena cava thrombus extending above the hepatic veins: a contemporary multicenter experience. Eur Urol. 2014 Sep; 66(3):584-92. Epub 2013 Nov 07.
    View PubMed
  8. Stewart SB, Cheville JC, Sebo TJ, Frank I, Boorjian SA, Thompson RH, Gettman MT, Tollefson MK, Umbriet EC, Psutka SP, Bergstralh EJ, Rangel L, Karnes RJ. Gleason grading after neoadjuvant hormonal therapy retains prognostic value for systemic progression following radical prostatectomy. Prostate Cancer Prostatic Dis. 2014 Aug 26.
    View PubMed
  9. Psutka SP, Boorjian SA, Lohse CM, Stewart SB, Tollefson MK, Cheville JC, Leibovich BC, Thompson RH. The association between metformin use and oncologic outcomes among surgically treated diabetic patients with localized renal cell carcinoma. Urol Oncol. 2014 Aug 18.
    View PubMed
  10. Lu J, Lonergan PE, Nacusi LP, Wang L, Schmidt LJ, Sun Z, Van der Steen T, Boorjian SA, Kosari F, Vasmatzis G, Klee GG, Balk SP, Huang H, Wang C, Tindall DJ. The cistrome and gene signature of androgen receptor splice variants in castration-resistant prostate cancer cells. J Urol. 2014 Aug 14.
    View PubMed
  11. Thompson RH, Atwell T, Schmit G, Lohse CM, Kurup AN, Weisbrod A, Psutka SP, Stewart SB, Callstrom MR, Cheville JC, Boorjian SA, Leibovich BC. Comparison of Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses. Eur Urol. 2014 Aug 06.
    View PubMed
  12. Welch BT, Callstrom MR, Morris JM, Kurup AN, Schmit GD, Weisbrod AJ, Lohse CM, Kohli M, Costello BA, Olivier KR, Thompson RH, Boorjian SA, Atwell TD. Feasibility and oncologic control after percutaneous image guided ablation of metastatic renal cell carcinoma. J Urol. 2014 Aug; 192(2):357-63. Epub 2014 Mar 12.
    View PubMed
  13. Ploussard G, Shariat SF, Dragomir A, Kluth LA, Xylinas E, Masson-Lecomte A, Rieken M, Rink M, Matsumoto K, Kikuchi E, Klatte T, Boorjian SA, Lotan Y, Roghmann F, Fairey AS, Fradet Y, Black PC, Rendon R, Izawa J, Kassouf W. Conditional Survival After Radical Cystectomy for Bladder Cancer: Evidence for a Patient Changing Risk Profile over Time. Eur Urol. 2014 Aug; 66(2):361-70. Epub 2013 Oct 09.
    View PubMed
  14. Gakis G, Boorjian SA, Briganti A, Joniau S, Karazanashvili G, Karnes RJ, Mattei A, Shariat SF, Stenzl A, Wirth M, Stief CG. The Role of Radical Prostatectomy and Lymph Node Dissection in Lymph Node-Positive Prostate Cancer: A Systematic Review of the Literature. Eur Urol. 2014 Aug; 66(2):191-9. Epub 2013 May 22.
    View PubMed
  15. Viers BR, Sukov WR, Gettman MT, Rangel LJ, Bergstralh EJ, Frank I, Tollefson MK, Thompson RH, Boorjian SA, Karnes RJ. Primary Gleason Grade 4 at the Positive Margin Is Associated with Metastasis and Death Among Patients with Gleason 7 Prostate Cancer Undergoing Radical Prostatectomy. Eur Urol. 2014 Jul 19.
    View PubMed
  16. Viers BR, Houston Thompson R, Boorjian SA, Lohse CM, Leibovich BC, Tollefson MK. Preoperative neutrophil-lymphocyte ratio predicts death among patients with localized clear cell renal carcinoma undergoing nephrectomy. Urol Oncol. 2014 Jul 10.
    View PubMed
  17. Scavonetto F, Yeoh TY, Umbreit EC, Weingarten TN, Gettman MT, Frank I, Boorjian SA, Karnes RJ, Schroeder DR, Rangel LJ, Hanson AC, Hofer RE, Sessler DI, Sprung J. Association between neuraxial analgesia, cancer progression, and mortality after radical prostatectomy: a large, retrospective matched cohort study. Br J Anaesth. 2014 Jul; 113 Suppl 1:i95-102. Epub 2013 Dec 16.
    View PubMed
  18. Plimack ER, Hoffman-Censits JH, Viterbo R, Trabulsi EJ, Ross EA, Greenberg RE, Chen DY, Lallas CD, Wong YN, Lin J, Kutikov A, Dotan E, Brennan TA, Palma N, Dulaimi E, Mehrazin R, Boorjian SA, Kelly WK, Uzzo RG, Hudes GR. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol. 2014 Jun 20; 32(18):1895-901. Epub 2014 May 12.
    View PubMed
  19. Linder BJ, Tarrell RF, Boorjian SA. Cystectomy for Refractory Hemorrhagic Cystitis: Contemporary Etiology, Presentation and Outcomes. J Urol. 2014 Jun 14.
    View PubMed
  20. Psutka SP, Stewart SB, Boorjian SA, Lohse CM, Tollefson MK, Cheville JC, Leibovich BC, Thompson RH. Diabetes Mellitus is Independently Associated with an Increased Risk of Mortality Among Clear Cell Renal Cell Carcinoma Patients. J Urol. 2014 Jun 12.
    View PubMed
  21. Knoedler JJ, Karnes RJ, Thompson RH, Rangel LJ, Bergstralh EJ, Boorjian SA. The association of tumor volume with mortality following radical prostatectomy. Prostate Cancer Prostatic Dis. 2014 Jun; 17(2):144-8. Epub 2014 Jan 28.
    View PubMed
  22. Clifton MM, Psutka SP, Boorjian SA, Cheville JC, Thapa P, Thompson RH, Tollefson MK, Karnes RJ, Frank I. Cancer-specific mortality following radical cystectomy for bladder cancer with lymph node involvement: impact of pathologic disease features and adjuvant chemotherapy. World J Urol. 2014 May 15.
    View PubMed
  23. Linder BJ, Boorjian SA, Hudolin T, Cheville JC, Thapa P, Tarrell RF, Frank I. Late recurrence after radical cystectomy: patterns, risk factors and outcomes. J Urol. 2014 May; 191(5):1256-61. Epub 2013 Dec 10.
    View PubMed
  24. Schneider SA, Sukov WR, Frank I, Boorjian SA, Costello BA, Tarrell RF, Thapa P, Houston Thompson R, Tollefson MK, Jeffrey Karnes R, Cheville JC. Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome. Mod Pathol. 2014 May; 27(5):758-64. Epub 2013 Nov 1
    View PubMed
  25. Thompson RH, Boorjian SA, Kim SP, Cheville JC, Thapa P, Tarrel R, Dronca R, Costello B, Frank I. Eligibility for neoadjuvant/adjuvant cisplatin-based chemotherapy among radical cystectomy patients. BJU Int. 2014 May; 113(5b):E17-21. Epub 2013 Sep 05.
    View PubMed
  26. Zhang BY, Thompson RH, Lohse CM, Leibovich BC, Boorjian SA, Cheville JC, Costello BA. A novel prognostic model for patients with sarcomatoid renal cell carcinoma. BJU Int. 2014 Apr 15.
    View PubMed
  27. Hegg RM, Schmit GD, Kurup AN, Weisbrod AJ, Boorjian SA, Atwell TD. Ultrasound-guided transhepatic radiofrequency ablation of renal tumors: a safe and effective approach. Cardiovasc Intervent Radiol. 2014 Apr; 37(2):508-12. Epub 2013 Aug 09.
    View PubMed
  28. Welch BT, Callstrom MR, Carpenter PC, Wass CT, Welch TL, Boorjian SA, Nichols DA, Thompson GB, Lohse CM, Erickson D, Leibovich BC, Atwell TD. A single-institution experience in image-guided thermal ablation of adrenal gland metastases. J Vasc Interv Radiol. 2014 Apr; 25(4):593-8. Epub 2014 Feb 06.
    View PubMed
  29. Schmit GD, Kurup AN, Weisbrod AJ, Thompson RH, Boorjian SA, Wass CT, Callstrom MR, Atwell TD. ABLATE: a renal ablation planning algorithm. AJR Am J Roentgenol. 2014 Apr; 202(4):894-903.
    View PubMed
  30. Abdollah F, Karnes RJ, Suardi N, Cozzarini C, Gandaglia G, Fossati N, Bianchi M, Boorjian SA, Sun M, Karakiewicz PI, Montorsi F, Briganti A. Predicting survival of patients with node-positive prostate cancer following multimodal treatment. Eur Urol. 2014 Mar; 65(3):554-62. Epub 2013 Sep 27
    View PubMed
  31. Tollefson MK, Karnes RJ, Rangel L, Carlson R, Boorjian SA. Blood type, lymphadenectomy and blood transfusion predict venous thromboembolic events following radical prostatectomy with pelvic lymphadenectomy. J Urol. 2014 Mar; 191(3):646-51. Epub 2013 Oct 17
    View PubMed
  32. Eisenberg MS, Thompson RH, Frank I, Kim SP, Cotter KJ, Tollefson MK, Kaushik D, Thapa P, Tarrell R, Boorjian SA. Long-term renal function outcomes after radical cystectomy. J Urol. 2014 Mar; 191(3):619-25. Epub 2013 Sep 12
    View PubMed
  33. Viers BR, Boorjian SA, Frank I, Tarrell RF, Thapa P, Karnes RJ, Thompson RH, Tollefson MK. Pretreatment Neutrophil-to-Lymphocyte Ratio Is Associated with Advanced Pathologic Tumor Stage and Increased Cancer-specific Mortality Among Patients with Urothelial Carcinoma of the Bladder Undergoing Radical Cystectomy. Eur Urol. 2014 Feb 26.
    View PubMed
  34. Yelfimov DA, Frank I, Boorjian SA, Thapa P, Cheville JC, Tollefson MK. Adjuvant chemotherapy is associated with decreased mortality after radical cystectomy for locally advanced bladder cancer. World J Urol. 2014 Jan 14.
    View PubMed
  35. Mikel Hubanks J, Boorjian SA, Frank I, Gettman MT, Houston Thompson R, Rangel LJ, Bergstralh EJ, Jeffrey Karnes R. The presence of extracapsular extension is associated with an increased risk of death from prostate cancer after radical prostatectomy for patients with seminal vesicle invasion and negative lymph nodes. Urol Oncol. 2014 Jan; 32(1):26.e1-7. Epub 2013 Feb 06.
    View PubMed
  36. Wang JK, Boorjian SA, Frank I, Tarrell RF, Thapa P, Jacob EK, Tauscher CD, Tollefson MK. Non-O blood type is associated with an increased risk of venous thromboembolism after radical cystectomy. Urology. 2014 Jan; 83(1):140-5. Epub 2013 Oct 16.
    View PubMed
  37. Xylinas E, Robinson BD, Kluth LA, Volkmer BG, Hautmann R, Kufer R, Zerbib M, Kwon E, Thompson RH, Boorjian SA, Shariat SF. Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. Eur J Surg Oncol. 2014 Jan; 40(1):121-7. Epub 2013 Sep 18
    View PubMed
  38. Raman JD, Lin YK, Kaag M, Atkinson T, Crispen P, Wille M, Smith N, Hockenberry M, Guzzo T, Peyronnet B, Bensalah K, Simhan J, Kutikov A, Cha E, Herman M, Scherr D, Shariat SF, Boorjian SA. High rates of advanced disease, complications, and decline of renal function after radical nephroureterectomy. Urol Oncol. 2014 Jan; 32(1):47.e9-14. Epub 2013 Oct 17.
    View PubMed
  39. Carrasco A, Thompson RH, Leibovich BC, Lohse CM, Cheville JC, Boorjian SA. The impact of histology on survival for patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy. Indian J Urol. 2014 Jan; 30(1):38-42.
    View PubMed
  40. Hubanks JM, Boorjian SA, Frank I, Gettman MT, Thompson RH, Rangel LJ, Bergstralh EJ, Karnes RJ. The presence of extracapsular extension is associated with an increased risk of death from prostate cancer after radical prostatectomy for patients with seminal vesicle invasion and negative lymph nodes. UROL. ONCOL. 2014; 32(1):26.e1-7.
  41. Kluth LA, Xylinas E, Rieken M, El Ghouayel M, Sun M, Karakiewicz PI, Lotan Y, Chun FKH, Boorjian SA, Lee RK, Briganti A, Roupret M, Fisch M, Scherr DS, Shariat SF. Impact of peri-operative blood transfusion on the outcomes of patients undergoing radical cystectomy for urothelial carcinoma of the bladder. BJU Int. 2014; 113(3):393-8.
  42. Breau RH, Karnes RJ, Farmer SA, Thapa P, Cagiannos I, Morash C, Frank I. Progression to detrusor muscle invasion during urothelial carcinoma surveillance is associated with poor prognosis. BJU Int. 2014; 113(6):900-6.
  43. Gakis G, Boorjian SA, Briganti A, Joniau S, Karazanashvili G, Karnes RJ, Mattei A, Shariat SF, Stenzl A, Wirth M, Stief CG. The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: A systematic review of the literature. Eur Urol. 2014; 66:191-9.
  44. Kaushik D, Frank I, Eisenberg MS, Cheville JC, Tarrell R, Thapa P, Thompson RH, Boorjian SA. Gender-specific survival following radical cystectomy for pT4 bladder cancer. World J Urol. 2013 Dec 21.
    View PubMed
  45. Kluth LA, Rieken M, Xylinas E, Kent M, Rink M, Roupret M, Sharifi N, Jamzadeh A, Kassouf W, Kaushik D, Boorjian SA, Roghmann F, Noldus J, Masson-Lecomte A, Vordos D, Ikeda M, Matsumoto K, Hagiwara M, Kikuchi E, Fradet Y, Izawa J, Rendon R, Fairey A, Gender-specific Differences in Clinicopathologic Outcomes Following Radical Cystectomy: An International Multi-institutional Study of More Than 8000 Patients. Eur Urol. 2013 Dec 05.
    View PubMed
  46. Eisenberg MS, Boorjian SA, Cheville JC, Thompson RH, Thapa P, Kaushik D, Frank I. The SPARC score: a multifactorial outcome prediction model for patients undergoing radical cystectomy for bladder cancer. J Urol. 2013 Dec; 190(6):2005-10. Epub 2013 Jun 14.
    View PubMed
  47. Kopparapu PK, Boorjian SA, Robinson BD, Downes M, Gudas LJ, Mongan NP, Persson JL. Expression of cyclin d1 and its association with disease characteristics in bladder cancer. Anticancer Res. 2013 Dec; 33(12):5235-42.
    View PubMed
  48. Tollefson MK, Boorjian SA, Gettman MT, Rangel LJ, Bergstralh EJ, Karnes RJ. Preoperative estimated glomerular filtration rate predicts overall mortality in patients undergoing radical prostatectomy. Urol Oncol. 2013 Nov; 31(8):1483-8. Epub 2012 May 10.
    View PubMed
  49. Linder BJ, Boorjian SA, Cheville JC, Sukov WR, Thapa P, Tarrell RF, Frank I. The impact of histological reclassification during pathology re-review--evidence of a Will Rogers effect in bladder cancer? J Urol. 2013 Nov; 190(5):1692-6. Epub 2013 May 23.
    View PubMed
  50. Eisenberg MS, Karnes RJ, Kaushik D, Rangel L, Bergstralh EJ, Boorjian SA. Risk stratification of patients with extraprostatic extension and negative lymph nodes at radical prostatectomy: identifying optimal candidates for adjuvant therapy. J Urol. 2013 Nov; 190(5):1735-41. Epub 2013 May 29.
    View PubMed
  51. Knoedler JJ, Boorjian SA, Tollefson MK, Cheville JC, Thapa P, Tarrell RF, Frank I. Urothelial Carcinoma Involving the Prostate: the Association of Revised Tumor Stage and Coexistent Bladder Cancer with Survival Following Radical Cystectomy. BJU Int. 2013 Oct 07. [Epub ahead of print]
    View PubMed
  52. Abdollah F, Boorjian S, Cozzarini C, Suardi N, Sun M, Fiorino C, di Muzio N, Karakiewicz PI, Montorsi F, Karnes RJ, Briganti A. Survival following biochemical recurrence after radical prostatectomy and adjuvant radiotherapy in patients with prostate cancer: the impact of competing causes of mortality and patient stratification. Eur Urol. 2013 Oct; 64(4):557-64. Epub 2013 Mar 13.
    View PubMed
  53. Kaushik D, Kim SP, Childs MA, Lohse CM, Costello BA, Cheville JC, Boorjian SA, Leibovich BC, Thompson RH. Overall survival and development of stage IV chronic kidney disease in patients undergoing partial and radical nephrectomy for benign renal tumors. Eur Urol. 2013 Oct; 64(4):600-6. Epub 2012 Dec 25.
    View PubMed
  54. Schmit GD, Thompson RH, Boorjian SA, McDonald RJ, Kurup AN, Weisbrod AJ, Kor DJ, Callstrom MR, Atwell TD. Percutaneous renal cryoablation in obese and morbidly obese patients. Urology. 2013 Sep; 82(3):636-41. Epub 2013 Jul 26.
    View PubMed
  55. Dobbs RW, Boorjian SA, Canter DJ. All men are created equal: benign prostatic hyperplasia, surgery, and politics. Urology. 2013 Sep; 82(3):508-10. Epub 2013 Jul 04.
    View PubMed
  56. Wang JK, Tollefson MK, Kim SP, Boorjian SA, Leibovich BC, Lohse CM, Cheville JC, Thompson RH. Iatrogenic splenectomy during nephrectomy for renal tumors. Int J Urol. 2013 Sep; 20(9):896-902. Epub 2013 Feb 04.
    View PubMed
  57. Kim SP, Shah ND, Weight CJ, Thompson RH, Wang JK, Karnes RJ, Han LC, Ziegenfuss JY, Frank I, Tollefson MK, Boorjian SA. Population-based trends in urinary diversion among patients undergoing radical cystectomy for bladder cancer. BJU Int. 2013 Aug; 112(4):478-84. Epub 2013 Mar 01.
    View PubMed
  58. Lotan Y, Amiel G, Boorjian SA, Clark PE, Droller M, Gingrich JR, Guzzo TJ, Inman BA, Kamat AM, Karsh L, Nielsen ME, Smith ND, Shariat SF, Svatek RS, Taylor JM, Bladder Cancer Think Tank, Bladder Cancer Advocacy Network. Comprehensive handbook for developing a bladder cancer cystectomy database. Urol Oncol. 2013 Aug; 31(6):812-26. Epub 2011 Nov 6
    View PubMed
  59. Linder BJ, Boorjian SA, Umbreit EC, Carlson RE, Rangel LJ, Bergstralh EJ, Karnes RJ. Interaction of adjuvant androgen deprivation therapy with patient comorbidity status on overall survival after radical prostatectomy for high-risk prostate cancer. Int J Urol. 2013 Aug; 20(8):798-805. Epub 2012 Dec 20.
    View PubMed
  60. Kaushik D, Linder BJ, Thompson RH, Eisenberg MS, Lohse CM, Cheville JC, Leibovich BC, Boorjian SA. The impact of histology on clinicopathologic outcomes for patients with renal cell carcinoma and venous tumor thrombus: a matched cohort analysis. Urology. 2013 Jul; 82(1):136-41. Epub 2013 May 01.
    View PubMed
  61. Boorjian SA, Kim SP, Tollefson MK, Carrasco A, Cheville JC, Thompson RH, Thapa P, Frank I. Comparative performance of comorbidity indices for estimating perioperative and 5-year all cause mortality following radical cystectomy for bladder cancer. J Urol. 2013 Jul; 190(1):55-60. Epub 2013 Jan 09.
    View PubMed
  62. Eisenberg MS, Cheville JC, Thompson RH, Kaushik D, Lohse CM, Boorjian SA, Costello BA, Leibovich BC. Association of microvascular and capillary-lymphatic invasion with outcome in patients with renal cell carcinoma. J Urol. 2013 Jul; 190(1):37-43. Epub 2013 Jan 23.
    View PubMed
  63. Kim SP, Shah ND, Karnes RJ, Weight CJ, Shippee ND, Han LC, Boorjian SA, Smaldone MC, Frank I, Gettman MT, Tollefson MK, Thompson RH. Hospitalization costs for radical prostatectomy attributable to robotic surgery. Eur Urol. 2013 Jul; 64(1):11-6. Epub 2012 Aug 20.
    View PubMed
  64. Michelena HI, Stulak J, Enriquez-Sarano M, Boorjian SA. Tumor thrombus. J Am Coll Cardiol. 2013 Jun 25; 61(25):e351. Epub 2013 Apr 17.
    View PubMed
  65. Kim SP, Karnes RJ, Nguyen PL, Ziegenfuss JY, Han LC, Thompson RH, Trinh QD, Sun M, Boorjian SA, Beebe TJ, Tilburt JC. Clinical implementation of quality of life instruments and prediction tools for localized prostate cancer: results from a national survey of radiation oncologists and urologists. J Urol. 2013 Jun; 189(6):2092-8. Epub 2012 Dec 03.
    View PubMed
  66. Kopparapu PK, Boorjian SA, Robinson BD, Downes M, Gudas LJ, Mongan NP, Persson JL. Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer. Anticancer Res. 2013 Jun; 33(6):2381-90.
    View PubMed
  67. Weight CJ, Kim SP, Jacobson DJ, McGree ME, Boorjian SA, Thompson RH, Leibovich BC, Karnes RJ, St Sauver J. The effect of benign lower urinary tract symptoms on subsequent prostate cancer testing and diagnosis. Eur Urol. 2013 Jun; 63(6):1021-7. Epub 2013 Jan 04.
    View PubMed
  68. Tollefson MK, Karnes RJ, Rangel LJ, Bergstralh EJ, Boorjian SA. The impact of clinical stage on prostate cancer survival following radical prostatectomy. J Urol. 2013 May; 189(5):1707-12. Epub 2012 Nov 15.
    View PubMed
  69. Linder BJ, Frank I, Cheville JC, Thompson RH, Thapa P, Tarrell RF, Boorjian SA. Outcomes following radical cystectomy for nested variant of urothelial carcinoma: a matched cohort analysis. J Urol. 2013 May; 189(5):1670-5. Epub 2012 Nov 06.
    View PubMed
  70. Weight CJ, Crispen PL, Breau RH, Kim SP, Lohse CM, Boorjian SA, Thompson RH, Leibovich BC. Practice-setting and surgeon characteristics heavily influence the decision to perform partial nephrectomy among American Urologic Association surgeons. BJU Int. 2013 May; 111(5):731-8. Epub 2012 Apr 13.
    View PubMed
  71. Linder BJ, Frank I, Cheville JC, Tollefson MK, Thompson RH, Tarrell RF, Thapa P, Boorjian SA. The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy. Eur Urol. 2013 May; 63(5):839-45. Epub 2013 Jan 11.
    View PubMed
  72. Kim SP, Leibovich BC, Shah ND, Weight CJ, Borah BJ, Han LC, Boorjian SA, Thompson RH. The relationship of postoperative complications with in-hospital outcomes and costs after renal surgery for kidney cancer. BJU Int. 2013 Apr; 111(4):580-8. Epub 2012 May 07.
    View PubMed
  73. Hegg RM, Schmit GD, Boorjian SA, McDonald RJ, Kurup AN, Weisbrod AJ, Callstrom MR, Atwell TD, Thompson RH. Percutaneous renal cryoablation after partial nephrectomy: technical feasibility, complications and outcomes. J Urol. 2013 Apr; 189(4):1243-8. Epub 2012 Oct 30.
    View PubMed
  74. Delahunt B, McKenney JK, Lohse CM, Leibovich BC, Thompson RH, Boorjian SA, Cheville JC. A novel grading system for clear cell renal cell carcinoma incorporating tumor necrosis. Am J Surg Pathol. 2013 Mar; 37(3):311-22.
    View PubMed
  75. Kim SP, Boorjian SA, Shah ND, Weight CJ, Tilburt JC, Han LC, Thompson RH, Trinh QD, Sun M, Moriarty JP, Karnes RJ. Disparities in access to hospitals with robotic surgery for patients with prostate cancer undergoing radical prostatectomy. J Urol. 2013 Feb; 189(2):514-20. Epub 2012 Dec 17.
    View PubMed
  76. Atwell TD, Schmit GD, Boorjian SA, Mandrekar J, Kurup AN, Weisbrod AJ, Chow GK, Leibovich BC, Callstrom MR, Patterson DE, Lohse CM, Thompson RH. Percutaneous ablation of renal masses measuring 3.0 cm and smaller: comparative local control and complications after radiofrequency ablation and cryoablation. AJR Am J Roentgenol. 2013 Feb; 200(2):461-6.
    View PubMed
  77. Schmit GD, Thompson RH, Kurup AN, Weisbrod AJ, Boorjian SA, Carter RE, Geske JR, Callstrom MR, Atwell TD. Usefulness of R.E.N.A.L. nephrometry scoring system for predicting outcomes and complications of percutaneous ablation of 751 renal tumors. J Urol. 2013 Jan; 189(1):30-5. Epub 2012 Nov 16.
    View PubMed
  78. Tollefson MK, Boorjian SA, Farmer SA, Frank I. Downstaging to non-invasive urothelial carcinoma is associated with improved outcome following radical cystectomy for patients with cT2 disease. World J Urol. 2012 Dec; 30(6):795-9. Epub 2012 Mar 25.
    View PubMed
  79. Mitchell CR, Boorjian SA, Umbreit EC, Rangel LJ, Carlson RE, Karnes RJ. 20-Year survival after radical prostatectomy as initial treatment for cT3 prostate cancer. BJU Int. 2012 Dec; 110(11):1709-13. Epub 2012 Aug 30.
    View PubMed
  80. Wang JK, Boorjian SA, Cheville JC, Kim SP, Tarrell RF, Thapa P, Frank I. Outcomes following radical cystectomy for micropapillary bladder cancer versus pure urothelial carcinoma: a matched cohort analysis. World J Urol. 2012 Dec; 30(6):801-6. Epub 2012 Nov 07.
    View PubMed
  81. Boorjian SA, Tollefson MK, Thompson RH, Rangel LJ, Bergstralh EJ, Karnes RJ. Natural history of biochemical recurrence after radical prostatectomy with adjuvant radiation therapy. J Urol. 2012 Nov; 188(5):1761-6. Epub 2012 Sep 19.
    View PubMed
  82. Zarei S, Frank I, Boorjian SA, Thompson RH, Kim S, Weight C, Tarrell R, Thapa P, Cheville JC. Prognostic significance of measured depth of invasion of urothelial carcinoma of the bladder compared to the 2010 American Joint Committee on Cancer pT2 and pT3 classifications. J Urol. 2012 Nov; 188(5):1706-11. Epub 2012 Sep 19.
    View PubMed
  83. Kim SP, Boorjian SA, Shah ND, Karnes RJ, Weight CJ, Moriarty JP, Tollefson MK, Shippee ND, Frank I. Contemporary trends of in-hospital complications and mortality for radical cystectomy. BJU Int. 2012 Oct; 110(8):1163-8. Epub 2012 Mar 22.
    View PubMed
  84. Knoedler JJ, Boorjian SA, Kim SP, Weight CJ, Thapa P, Tarrell RF, Cheville JC, Frank I. Does partial cystectomy compromise oncologic outcomes for patients with bladder cancer compared to radical cystectomy? A matched case-control analysis. J Urol. 2012 Oct; 188(4):1115-9. Epub 2012 Aug 15.
    View PubMed
  85. Kim SP, Crispen PL, Thompson RH, Weight CJ, Boorjian SA, Costello BA, Lohse CM, Leibovich BC. Assessment of the pathologic inclusion criteria from contemporary adjuvant clinical trials for predicting disease progression after nephrectomy for renal cell carcinoma. Cancer. 2012 Sep 15; 118(18):4412-20. Epub 2012 Jan 03.
    View PubMed
  86. Semenas J, Allegrucci C, Boorjian SA, Mongan NP, Persson JL. Overcoming drug resistance and treating advanced prostate cancer. Curr Drug Targets. 2012 Sep 1; 13(10):1308-23.
    View PubMed
  87. Kim SP, Frank I, Cheville JC, Thompson RH, Weight CJ, Thapa P, Boorjian SA. The impact of squamous and glandular differentiation on survival after radical cystectomy for urothelial carcinoma. J Urol. 2012 Aug; 188(2):405-9. Epub 2012 Jun 14.
    View PubMed
  88. Kim SP, Thompson RH, Boorjian SA, Weight CJ, Han LC, Murad MH, Shippee ND, Erwin PJ, Costello BA, Chow GK, Leibovich BC. Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: a systematic review and meta-analysis. J Urol. 2012 Jul; 188(1):51-7. Epub 2012 May 14.
    View PubMed
  89. Kim SP, Shah ND, Karnes RJ, Weight CJ, Frank I, Moriarty JP, Han LC, Borah B, Tollefson MK, Boorjian SA. The implications of hospital acquired adverse events on mortality, length of stay and costs for patients undergoing radical cystectomy for bladder cancer. J Urol. 2012 Jun; 187(6):2011-7. Epub 2012 Apr 11.
    View PubMed
  90. Bastian PJ, Boorjian SA, Bossi A, Briganti A, Heidenreich A, Freedland SJ, Montorsi F, Roach M 3rd, Schroder F, van Poppel H, Stief CG, Stephenson AJ, Zelefsky MJ. High-risk prostate cancer: from definition to contemporary management. Eur Urol. 2012 Jun; 61(6):1096-106. Epub 2012 Feb 24.
    View PubMed
  91. Boorjian SA, Eastham JA, Graefen M, Guillonneau B, Karnes RJ, Moul JW, Schaeffer EM, Stief C, Zorn KC. A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. Eur Urol. 2012 Apr; 61(4):664-75. Epub 2011 Dec 07.
    View PubMed
  92. Boorjian SA, Tollefson MK, Rangel LJ, Bergstralh EJ, Karnes RJ. Clinicopathological predictors of systemic progression and prostate cancer mortality in patients with a positive surgical margin at radical prostatectomy. Prostate Cancer Prostatic Dis. 2012 Mar; 15(1):56-62. Epub 2011 Aug 02.
    View PubMed
  93. Clements T, Messer JC, Terrell JD, Herman MP, Ng CK, Scherr DS, Scoll B, Boorjian SA, Uzzo RG, Wille M, Eggener SE, Lucas SM, Lotan Y, Shariat SF, Raman JD. High-grade ureteroscopic biopsy is associated with advanced pathology of upper-tract urothelial carcinoma tumors at definitive surgical resection. J Endourol. Epub 2012 Feb 24.
  94. Long CJ, Canter DJ, Kutikov A, Li T, Simhan J, Smaldone M, Teper E, Viterbo R, Boorjian SA, Chen DYT, Greenberg RE, Uzzo RG. Partial nephrectomy for renal masses ≥ 7 cm: technical, oncological and functional outcomes. BJU Int. Epub 2012 Jan 5.
  95. Atwell TD, Carter RE, Schmit GD, Carr CM, Boorjian SA, Curry TB, Thompson RH, Kurup AN, Weisbrod AJ, Chow GK, Leibovich BC, Callstrom MR, Patterson DE. Complications following 573 percutaneous renal radiofrequency and cryoablation procedures. J Vasc Interv Radiol. 2012 Jan; 23(1):48-54. Epub 2011 Oct 28.
    View PubMed
  96. Marcinkiewicz K, Scotland KB, Boorjian SA, Nilsson EM, Persson JL, Abrahamsson PA, Allegrucci C, Hughes IA, Gudas LJ, Mongan NP. The androgen receptor and stem cell pathways in prostate and bladder cancers (review). Int J Oncol. 2012 Jan; 40(1):5-12. Epub 2011 Sep 28.
    View PubMed
  97. Kutikov A, Cooperberg MR, Paciorek AT, Uzzo RG, Carroll PR, Boorjian SA. Evaluating prostate cancer mortality and competing risks of death in patients with localized prostate cancer using a comprehensive nomogram. Prostate Cancer and Prostatic Diseases. 2012; 15(4):374-9.
  98. Inman BA, Frank I, Boorjian SA, Akornor JW, Karnes RJ, Leibovich BC, Blute ML, Bergstralh EJ. Dynamic prediction of metastases after radical prostatectomy for prostate cancer. BJU Int. 2011 Dec; 108(11):1762-8. Epub 2011 May 26.
    View PubMed
  99. Boorjian SA, Kim SP, Weight CJ, Cheville JC, Thapa P, Frank I. Risk factors and outcomes of urethral recurrence following radical cystectomy. Eur Urol. 2011 Dec; 60(6):1266-72. Epub 2011 Aug 22.
    View PubMed
  100. Kim SP, Weight CJ, Leibovich BC, Thompson RH, Costello BA, Cheville JC, Lohse CM, Boorjian SA. Outcomes and clinicopathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma. Urology. 2011 Nov; 78(5):1101-6. Epub 2011 Sep 08.
    View PubMed
  101. Kim SP, Shah ND, Weight CJ, Thompson RH, Moriarty JP, Shippee ND, Costello BA, Boorjian SA, Leibovich BC. Contemporary trends in nephrectomy for renal cell carcinoma in the United States: results from a population based cohort. J Urol. 2011 Nov; 186(5):1779-85. Epub 2011 Sep 25.
    View PubMed
  102. Boorjian SA, Tollefson MK, Cheville JC, Costello BA, Thapa P, Frank I. Detection of asymptomatic recurrence during routine oncological followup after radical cystectomy is associated with improved patient survival. J Urol. 2011 Nov; 186(5):1796-802. Epub 2011 Sep 25.
    View PubMed
  103. Mitchell CR, Atwell TD, Weisbrod AJ, Lohse CM, Boorjian SA, Leibovich BC, Thompson RH. Renal function outcomes in patients treated with partial nephrectomy versus percutaneous ablation for renal tumors in a solitary kidney. J Urol. 2011 Nov; 186(5):1786-90. Epub 2011 Sep 25.
    View PubMed
  104. Weight CJ, Atwell TD, Fazzio RT, Kim SP, Kenny M, Lohse CM, Boorjian SA, Leibovich BC, Thompson RH. A multidisciplinary evaluation of inter-reviewer agreement of the nephrometry score and the prediction of long-term outcomes. J Urol. 2011 Oct; 186(4):1223-8. Epub 2011 Aug 17.
    View PubMed
  105. Messer JC, Terrell JD, Herman MP, Ng CK, Scherr DS, Scoll B, Boorjian SA, Uzzo RG, Wille M, Eggener SE, Lucas SM, Lotan Y, Shariat SF, Raman JD. Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma. Urol Oncol. Epub 2011 Sep 7.
  106. Weight CJ, Kim SP, Lohse CM, Cheville JC, Thompson RH, Boorjian SA, Leibovich BC. Routine adrenalectomy in patients with locally advanced renal cell cancer does not offer oncologic benefit and places a significant portion of patients at risk for an asynchronous metastasis in a solitary adrenal gland. Eur Urol. 2011 Sep; 60(3):458-64. Epub 2011 Apr 16.
    View PubMed
  107. Messer J, Shariat SF, Brien JC, Herman MP, Ng CK, Scherr DS, Scoll B, Uzzo RG, Wille M, Eggener SE, Steinberg G, Terrell JD, Lucas SM, Lotan Y, Boorjian SA, Raman JD. Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU Int. 2011 Sep; 108(5):701-5. Epub 2011 Feb 14.
    View PubMed
  108. Kutikov A, Smaldone MC, Egleston BL, Manley BJ, Canter DJ, Simhan J, Boorjian SA, Viterbo R, Chen DY, Greenberg RE, Uzzo RG. Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephrometry score. Eur Urol. 2011 Aug; 60(2):241-8. Epub 2011 Apr 1.
    View PubMed
  109. Alt AL, Boorjian SA, Lohse CM, Costello BA, Leibovich BC, Blute ML. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer. 2011 Jul 1; 117(13):2873-82. Epub 2011 Jan 10.
    View PubMed
  110. Boorjian SA, Karnes RJ, Viterbo R, Rangel LJ, Bergstralh EJ, Horwitz EM, Blute ML, Buyyounouski MK. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer. 2011 Jul 1; 117(13):2883-91. Epub 2011 Jan 10.
    View PubMed
  111. Makhlin I, Zhang J, Long CJ, Devarajan K, Zhou Y, Klein-Szanto AJ, Huang M, Chernoff J, Boorjian SA. The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers. BJU Int. 2011 Jul; 108(2 Pt 2):E84-90. Epub 2010 Nov 02.
    View PubMed
  112. Boorjian SA, Thompson RH, Tollefson MK, Rangel LJ, Bergstralh EJ, Blute ML, Karnes RJ. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol. 2011 Jun; 59(6):893-9. Epub 2011 Feb 22.
    View PubMed
  113. Long CJ, Kutikov A, Canter DJ, Egleston BL, Chen DY, Viterbo R, Boorjian SA, Uzzo RG. Percutaneous vs surgical cryoablation of the small renal mass: is efficacy compromised? BJU Int. 2011 May; 107(9):1376-80. Epub 2010 Nov 09.
    View PubMed
  114. Kutikov A, Piotrowski ZJ, Canter DJ, Li T, Chen DY, Viterbo R, Greenberg RE, Boorjian SA, Uzzo RG. Routine adrenalectomy is unnecessary during surgery for large and/or upper pole renal tumors when the adrenal gland is radiographically normal. J Urol. 2011 Apr; 185(4):1198-203. Epub 2011 Feb 22.
    View PubMed
  115. Giri VN, Ruth K, Hughes L, Uzzo RG, Chen DY, Boorjian SA, Viterbo R, Rebbeck TR. Racial differences in prediction of time to prostate cancer diagnosis in a prospective screening cohort of high-risk men: effect of TMPRSS2 Met160Val. BJU Int. 2011 Feb; 107(3):466-70. Epub 2010 Aug 24.
    View PubMed
  116. Siddiqui SA, Boorjian SA, Blute ML, Rangel LJ, Bergstralh EJ, Karnes RJ, Frank I. Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer. BJU Int. 2011 Feb; 107(3):383-8.
    View PubMed
  117. Lane BR, Russo P, Uzzo RG, Hernandez AV, Boorjian SA, Thompson RH, Fergany AF, Love TE, Campbell SC. Comparison of cold and warm ischemia during partial nephrectomy in 660 solitary kidneys reveals predominant role of nonmodifiable factors in determining ultimate renal function. J Urol. 2011 Feb; 185(2):421-7. Epub 2010 Dec 17.
    View PubMed
  118. Canter D, Long C, Kutikov A, Plimack E, Saad I, Oblaczynski M, Zhu F, Viterbo R, Chen DY, Uzzo RG, Greenberg RE, Boorjian SA. Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy. BJU Int. 2011 Jan; 107(1):58-62.
    View PubMed
  119. Canter D, Viterbo R, Kutikov A, Wong YN, Plimack E, Zhu F, Oblaczynski M, Berberian R, Chen DY, Greenberg RE, Uzzo RG, Boorjian SA. Baseline renal function status limits patient eligibility to receive perioperative chemotherapy for invasive bladder cancer and is minimally affected by radical cystectomy. Urology. 2011 Jan; 77(1):160-5. Epub 2010 Aug 14.
    View PubMed
  120. Kim SP, Shah ND, Weight CJ, Thompson RH, Moriarty JP, Shippee ND, Costello BA, Boorjian SA, Leibovich BC. Contemporary trends in nephrectomy for renal cell carcinoma in the United States: Results from a population based cohort. International Braz J Urol. 2011; 37(5):663.
  121. Barbieri CE, Schwartz MJ, Boorjian SA, Lee MM, Scherr DS. Ureteroileal anastomosis with intraluminal visualization: technique and outcomes. Urology. 2010 Dec; 76(6):1496-500. Epub 2010 Apr 09.
    View PubMed
  122. Tollefson MK, Boorjian SA, Lohse CM, Blute ML, Leibovich BC. The impact of family history on pathological and clinical outcomes in non-syndromic clear cell renal cell carcinoma. BJU Int. 2010 Dec; 106(11):1638-42.
    View PubMed
  123. Canter D, Greenberg RE, Horwitz EM, Kutikov A, Li J, Long C, Buyyounouski M, Boorjian SA. Implantation of electromagnetic transponders following radical prostatectomy for delivery of IMRT. Can J Urol. 2010 Oct; 17(5):5365-9.
    View PubMed
  124. Boorjian SA, Zhu F, Herr HW. The effect of gender on response to bacillus Calmette-Guerin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder. BJU Int. 2010 Aug; 106(3):357-61. Epub 2009 Dec 11.
    View PubMed
  125. Aron M, Gill IS, Boorjian SA, Uzzo RG. Treatment of the 2 to 3 cm renal mass. J Urol. 2010 Aug; 184(2):419-22. Epub 2010 Jun 17.
    View PubMed
  126. Fogg RN, Boorjian SA. The sexual dysfunction of Louis XVI: a consequence of international politics, anatomy, or naivete? BJU Int. 2010 Aug; 106(4):457-9. Epub 2010 Jul 07.
    View PubMed
  127. Kutikov A, Uzzo RG, Caraway A, Reese CT, Egleston BL, Chen DY, Viterbo R, Greenberg RE, Wong YN, Raman JD, Boorjian SA. Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. BJU Int. 2010 Jul; 106(2):218-23. Epub 2009 Nov 17.
    View PubMed
  128. Brien JC, Shariat SF, Herman MP, Ng CK, Scherr DS, Scoll B, Uzzo RG, Wille M, Eggener SE, Terrell JD, Lucas SM, Lotan Y, Boorjian SA, Raman JD. Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. J Urol. 2010 Jul; 184(1):69-73. Epub 2010 May 15.
    View PubMed
  129. Scoll BJ, Uzzo RG, Chen DY, Boorjian SA, Kutikov A, Manley BJ, Viterbo R. Robot-assisted partial nephrectomy: a large single-institutional experience. Urology. 2010 Jun; 75(6):1328-34. Epub 2010 Jan 18.
    View PubMed
  130. Tollefson MK, Blute ML, Rangel LJ, Bergstralh EJ, Boorjian SA, Karnes RJ. The effect of Gleason score on the predictive value of prostate-specific antigen doubling time. BJU Int. 2010 May; 105(10):1381-5. Epub 2009 Oct 26.
    View PubMed
  131. Leibovich BC, Lohse CM, Crispen PL, Boorjian SA, Thompson RH, Blute ML, Cheville JC. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol. 2010 Apr; 183(4):1309-15. Epub 2010 Feb 19.
    View PubMed
  132. Boorjian SA, Karnes RJ, Crispen PL, Carlson RE, Rangel LJ, Bergstralh EJ, Blute ML. The impact of positive surgical margins on mortality following radical prostatectomy during the prostate specific antigen era. J Urol. 2010 Mar; 183(3):1003-9. Epub 2010 Jan 21.
    View PubMed
  133. Kaplan DJ, Boorjian SA, Ruth K, Egleston BL, Chen DY, Viterbo R, Uzzo RG, Buyyounouski MK, Raysor S, Giri VN. Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high-risk screening population. BJU Int. 2010 Feb; 105(3):334-7. Epub 2009 Aug 25.
    View PubMed
  134. Boorjian SA, Sheinin Y, Crispen PL, Lohse CM, Leibovich BC, Kwon ED. T-cell co-regulatory molecule expression in renal angiomyolipoma and pulmonary lymphangioleiomyomatosis. Urology. 2009 Dec; 74(6):1359-64. Epub 2009 Jun 07.
    View PubMed
  135. Boorjian SA, Karnes RJ, Crispen PL, Rangel LJ, Bergstralh EJ, Blute ML. Radiation therapy after radical prostatectomy: impact on metastasis and survival. J Urol. 2009 Dec; 182(6):2708-14.
    View PubMed
  136. Boorjian SA, Berglund RK, Maschino AC, Savage CJ, Herr HW. Fibrin clot inhibitor medication and efficacy of bacillus Calmette-Guerin for bladder urothelial cancer. J Urol. 2009 Oct; 182(4):1306-12. Epub 2009 Aug 14.
    View PubMed
  137. McGee SM, Boorjian SA, Karnes RJ. Carcinosarcoma of the prostate replacing the entire lower genitourinary tract. Urology. 2009 Sep; 74(3):540-1. Epub 2009 Jul 08.
    View PubMed
  138. Boorjian SA, Blute ML. Surgery for vena caval tumor extension in renal cancer. Curr Opin Urol. 2009 Sep; 19(5):473-7.
    View PubMed
  139. Crispen PL, Viterbo R, Boorjian SA, Greenberg RE, Chen DY, Uzzo RG. Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance. Cancer. 2009 Jul 1; 115(13):2844-52.
    View PubMed
  140. Boorjian SA, Uzzo RG. The evolving management of small renal masses. Curr Oncol Rep. 2009 May; 11(3):211-7.
    View PubMed
  141. Chavin G, Sheinin Y, Crispen PL, Boorjian SA, Roth TJ, Rangel L, Blute ML, Sebo TJ, Tindall DJ, Kwon ED, Karnes RJ. Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases. Clin Cancer Res. 2009 Mar 15; 15(6):2174-80. Epub 2009 Mar 10.
    View PubMed
  142. Boorjian SA, Heemers HV, Frank I, Farmer SA, Schmidt LJ, Sebo TJ, Tindall DJ. Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder. Endocr Relat Cancer. 2009 Mar; 16(1):123-37. Epub 2008 Oct 09.
    View PubMed
  143. Boorjian SA, Karnes RJ, Crispen PL, Rangel LJ, Bergstralh EJ, Sebo TJ, Blute ML. The impact of discordance between biopsy and pathological Gleason scores on survival after radical prostatectomy. J Urol. 2009 Jan; 181(1):95-104; discussion 104. Epub 2008 Nov 13.
    View PubMed
  144. Granberg CF, Boorjian SA, Crispen PL, Tollefson MK, Farmer SA, Frank I, Blute ML. Functional and oncological outcomes after orthotopic neobladder reconstruction in women. BJU Int. 2008 Dec; 102(11):1551-5. Epub 2008 Oct 08.
    View PubMed
  145. Crispen PL, Boorjian SA, Lohse CM, Sebo TS, Cheville JC, Blute ML, Leibovich BC. Outcomes following partial nephrectomy by tumor size. J Urol. 2008 Nov; 180(5):1912-7. Epub 2008 Sep 17.
    View PubMed
  146. Boorjian SA, Sheinin Y, Crispen PL, Lohse CM, Kwon ED, Leibovich BC. Hormone receptor expression in renal angiomyolipoma: clinicopathologic correlation. Urology. 2008 Oct; 72(4):927-32. Epub 2008 Mar 28.
    View PubMed
  147. Boorjian SA, Crispen PL, Lohse CM, Leibovich BC, Blute ML. The impact of temporal presentation on clinical and pathological outcomes for patients with sporadic bilateral renal masses. Eur Urol. 2008 Oct; 54(4):855-63. Epub 2008 May 09.
    View PubMed
  148. Boorjian SA, Blute ML. Surgical management of high risk prostate cancer: the Mayo Clinic experience. Urol Oncol. 2008 Sep-Oct; 26(5):530-2.
    View PubMed
  149. Crispen PL, Sheinin Y, Roth TJ, Lohse CM, Kuntz SM, Frigola X, Thompson RH, Boorjian SA, Dong H, Leibovich BC, Blute ML, Kwon ED. Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res. 2008 Aug 15; 14(16):5150-7. Epub 2008 Aug 11.
    View PubMed
  150. Crispen PL, Boorjian SA, Lohse CM, Leibovich BC, Kwon ED. Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers. Cancer. 2008 Aug 1; 113(3):450-60.
    View PubMed
  151. Boorjian SA, Sheinin Y, Crispen PL, Farmer SA, Lohse CM, Kuntz SM, Leibovich BC, Kwon ED, Frank I. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res. 2008 Aug 1; 14(15):4800-8.
    View PubMed
  152. Granberg CF, Boorjian SA, Schaff HV, Orszulak TA, Leibovich BC, Lohse CM, Cheville JC, Blute ML. Surgical management, complications, and outcome of radical nephrectomy with inferior vena cava tumor thrombectomy facilitated by vascular bypass. Urology. 2008 Jul; 72(1):148-52. Epub 2008 Apr 18.
    View PubMed
  153. Boorjian SA, Crispen PL, Lohse CM, Leibovich BC, Blute ML. Surgical resection of isolated retroperitoneal lymph node recurrence of renal cell carcinoma following nephrectomy. J Urol. 2008 Jul; 180(1):99-103; discussion 103. Epub 2008 May 15.
    View PubMed
  154. Boorjian SA, Crispen PL, Carlson RE, Rangel LJ, Karnes RJ, Frank I, Gettman MT. Impact of obesity on clinicopathologic outcomes after robot-assisted laparoscopic prostatectomy. J Endourol. 2008 Jul; 22(7):1471-6.
    View PubMed
  155. Boorjian SA, Gettman MT. Advances in robotic prostatectomy. Curr Urol Rep. 2008 May; 9(3):250-6.
    View PubMed
  156. Siddiqui SA, Boorjian SA, Inman B, Bagniewski S, Bergstralh EJ, Blute ML. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. J Urol. 2008 May; 179(5):1830-7; discussion 1837. Epub 2008 Mar 18.
    View PubMed
  157. Boorjian SA, Karnes RJ, Rangel LJ, Bergstralh EJ, Blute ML. Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy. J Urol. 2008 Apr; 179(4):1354-60; discussion 1360-1. Epub 2008 Mar 04.
    View PubMed
  158. Thompson RH, Boorjian SA, Lohse CM, Leibovich BC, Kwon ED, Cheville JC, Blute ML. Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol. 2008 Feb; 179(2):468-71; discussion 472-3.
    View PubMed
  159. Boorjian SA, Karnes RJ, Rangel LJ, Bergstralh EJ, Frank I, Blute ML. Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8-10 cancers. BJU Int. 2008 Feb; 101(3):299-304. Epub 2007 Oct 08.
    View PubMed
  160. Boorjian SA, Frank I, Inman B, Lohse CM, Cheville JC, Leibovich BC, Blute ML. The role of partial nephrectomy for the management of sporadic renal angiomyolipoma. Urology. 2007 Dec; 70(6):1064-8.
    View PubMed
  161. Boorjian SA, Thompson RH, Siddiqui S, Bagniewski S, Bergstralh EJ, Karnes RJ, Frank I, Blute ML. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol. 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. Epub 2007 Jul 16.
    View PubMed
  162. Blute ML, Boorjian SA, Leibovich BC, Lohse CM, Frank I, Karnes RJ. Results of inferior vena caval interruption by greenfield filter, ligation or resection during radical nephrectomy and tumor thrombectomy. J Urol. 2007 Aug; 178(2):440-5; discussion 444. Epub 2007 Jun 11.
    View PubMed
  163. Boorjian SA, Sengupta S, Blute ML. Renal cell carcinoma: vena caval involvement. BJU Int. 2007 May; 99(5 Pt B):1239-44.
    View PubMed
  164. Boorjian SA, Milowsky MI, Kaplan J, Albert M, Cobham MV, Coll DM, Mongan NP, Shelton G, Petrylak D, Gudas LJ, Nanus DM. Phase I/II Clinical Trial of Interferon Alfa-2b and Weekly Liposome-Encapsulated All-Trans Retinoic Acid in Patients with Advanced Renal Cell Carcinoma. J Immunother. 2007; 30:655-662.
  165. Boorjian S, Cowan JE, Konety BR, DuChane J, Tewari A, Carroll PR, Kane CJ, the CaPSURE Investigators. Bladder Cancer Incidence and Risk Factors Among Men With Prostate Cancer: Results from CaPSURE. J Urol. 2007; 177:883-8.
  166. Boorjian S, Hopps CV, Ghaly SW, Mulhall JP. The Utility of Sildenafil Citrate for Infertile Men with Sexual Dysfunction: A Pilot Study. BJU Int. 2007; 100:603-6.
  167. Boorjian S, Vaughan ED Jr, Pitts WR Jr, Muecke EC. Victor Fray Marshall: Twentieth Century Renaissance Urologist. J Urol. 2006; 175:43-5.
  168. Loyd E, Boorjian S. A Painless Testicular Mass in a 50-Year Old Man. Leydig cell tumor of the testis, microcystic variant. Arch Pathol Lab Med. 2006; 130:e39-40.
  169. Vickers AJ, Bianco FJ Jr, Boorjian S, Scardino PT, Eastham JA. Does Delay To Surgery Increase the Risk of Recurrence After Radical Prostatectomy? Cancer. 2006; 106:576-80.
  170. Lee R, AL-Ahmadie HA, Boorjian SA, Gonzalez RR, Badillo C, Badillo F, Reuter VE, Steckel J. A Case of Incidental Adrenocortical Oncocytoma. Nat Clin Pract Urol. 2006; 3:618-621.
  171. Raman JD, Palese MA, Ng CK, Boorjian SA, Scherr DS, Del Pizzo JJ, Sosa RE. Hand-Assisted Laparoscopic Nephroureterectomy for Upper Urinary Tract Transitional Cell Carcinoma. JSLS. 2006; 10:432-8.
  172. Boorjian S, Scherr DS, Mongan NP, Zhuang Y, Nanus DM, Gudas LJ. Retinoid Receptor mRNA Expression Profiles in Human Bladder Cancer Specimens. Int J Oncol. 2005; 26:1041-8.
  173. Boorjian SA, Bianco FJ Jr, Scardino PT, Eastham JA. Does the Time From Biopsy to Surgery Affect Biochemical Recurrence After Radical Prostatectomy? BJU Int. 2005; 96:773-6.
  174. Boorjian S, Ng C, Munver R, Palese MA, Vaughan ED Jr, Sosa RE, Del Pizzo JJ, Scherr DS. The Impact of Delay to Nephroureterectomy for Patients Undergoing Ureteroscopic Biopsy and Laser Tumor Ablation of Upper Tract Transitional Cell Carcinoma. Urology. 2005; 66:283-7.
  175. Raman JD, Ng CK, Boorjian SA, Sosa RE, Vaughan ED Jr, Scherr DS. Bladder Cancer Following Management of Upper Urinary Tract Transitional Cell Carcinoma: Predictive Factors and Pathology. BJU Int. 2005; 96:1031-1035.
  176. Raman JD, Mongan NP, Tickoo SK, Boorjian SA, Scherr DS, Gudas LG. Increased Expression of the Polycomb Group Gene, EZH2, in Transitional Cell Carcinoma of the Bladder. Clin Cancer Res. 2005; 11:8570-8576.
  177. Barocas DA, Kawamoto H, Dreizin DF, Howard ME, Choi J, Pitts WR, You X, Tickoo SK, Boorjian SA, Scherr DS. Five-alpha-reductase Expression in Benign and Malignant Urothelium; Correlation with Disease Characteristics and Outcome. Urology. 2005; 66:1134-1139.
  178. Boorjian S, Tickoo SK, Mongan NM, Yu H, Bok D, Rando RR, Nanus DM, Scherr DS, Gudas LJ. Reduced Lecithin:Retinol Acyltransferase (LRAT) Expression Correlates with Increased Pathologic Tumor Stage in Bladder Cancer. Clin Cancer Res. 2004; 10:3429-37.
  179. Boorjian S, Lipkin M, Goldstein M. The Impact of Obstructive Interval and Sperm Granuloma on Outcome of Vasectomy Reversal. J Urol. 2004; 171:304-6.
  180. Boorjian S, Ugras S, Mongan NP, Gudas LG, Tickoo SK, Scherr DS. Androgen Receptor Expression is Inversely Correlated with Pathologic Tumor Stage in Transitional Cell Carcinoma of the Bladder. Urology. 2004; 64:383-8.
  181. Boorjian S, Munver R, Sosa RE, aDel Pizzo JJ. Right Laparoscopic Live Donor Nephrectomy: A Single Institution Experience. Transplantation. 2004; 77:437-40.
  182. Boorjian S, Ng C, Munver R, Palese MA, Sosa RE, Vaughan ED Jr, Del Pizzo JJ, Scherr DS. Abnormal Selective Cytology Predicts Tumor Recurrence in Upper Tract Transitional Cell Carcinoma Treated with Ureteroscopic Laser Ablation. J Endourol. 2004; 18:912-6.
  183. Mulhall JP, Creech SD, Boorjian SA, Ghaly S, Kim ED, Moty A, Davis R, Hellstrom W. Subjective and Objective Analysis of the Prevalence of Peyronie’s Disease in a Population of Men Presenting for Prostate Cancer Screening. J Urol. 2004; 171:2350-2353.
  184. Anger JT, Wang GJ, Boorjian SA, Goldstein M. Sperm Cryopreservation and In Vitro Fertilization/Intracytoplasmic Sperm Injection in Men with Congenital Bilateral Absence of the Vas Deferens: A Success Story. Fertil Steril. 2004; 82:1452-1454.
  185. Machluf M, Orsola A, Boorjian S, Kershen R, Atala A. Microencapsulation of Leydig Cells: A System for Testosterone Supplementation. Endocrinology. 2003; 144:4975-9.
  186. Boorjian S, Choi BB, Loo MH, Kim P, Sandhu J. A rare case of painless gross hematuria: primary localized AA-type amyloidosis of the urinary bladder. Urology. 2002 Jan; 59(1):137.
    View PubMed